An observational study in Toxoplasmosis, sponsored by University Hospital, Clermont-Ferrand. Not yet recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2025-07-11.
Sponsored by University Hospital, Clermont-Ferrand · Observational
Toxoplasmosis in immunocompromised patients is a serious, life-threatening condition that requires rapid, appropriate treatment. Diagnosis is based on PCR, notably on blood samples. Systematic blood screening is carried out for patients most at risk, to detect the disease at an early stage. Detection of parasite DNA in blood in asymptomatic patients is possible, in the absence of Toxoplasma multiplication. It has previously been proposed a distinction of two entities: toxoplasmosis disease (clinical, biological and imaging evidence of toxoplasmosis) and toxoplasmosis infection (positive PCR in the blood in the absence of clinical or radiological evidence, without progression to toxoplasmosis). Since the clinical signs of toxoplasmosis are often aspecific, a positive PCR may be the first warning result, making it difficult to determine whether the patient will progress to toxoplasmosis disease or toxoplasmosis infection.
In collaboration with the French National Reference Center for toxoplasmosis, we are proposing a retrospective multicenter study to identify possible clinical, biological or imaging criteria pointing to toxoplasmosis disease or toxoplasmosis infection as soon as the first T. gondii PCR result is positive in the blood.
29 studies on the registry are indexed under Toxoplasmosis; 8 are open to participants now.
This study's planned enrollment of 100 is close to the median of 100 across 10 observational studies indexed under Toxoplasmosis.
Browse Toxoplasmosis studies →University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 179 are open to participants now.
Counted across the registry records on this site, refreshed daily.
-patient care at one of the participating centers
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Demographic data: age
expressed in years old
Time frame: 1 year
Demographic data: sex
choice between male/female
Time frame: 1 year
time between transplantation and positive T. gondii PCR
expressed in number of days
Time frame: 1 year
Underlying disease
for example: acute leukemia, solid organ transplant, ...
Time frame: 1 year
Ongoing anti-T. gondii prophylaxis
molecule name
Time frame: 1 year
PCR Ct value at diagnosis
number of cycle threshold
Time frame: 1 year
Outcome 1 month after first positive PCR
death or alive
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2025; primary completion for Dec 2025, 3 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →